Emergo Therapeutics announces successful completion of Phase 2a trial
DURHAM, N.C. – August 6, 2019 – Emergo Therapeutics has successfully completed their Phase 2a trial for their novel candidate norketotifen (NKT). The trial is yet another step forward in addressing the symptoms of the flu and flu-like illness.
Emergo Therapeutics Board of Directors welcomes Jack Bailey, President, GSK Pharmaceuticals USA
DURHAM, N.C. – May 29, 2019 – Emergo Therapeutics, which continues to accelerate its lead candidate norketotifen through Phase 2 studies, has added another seasoned executive to its Board of Directors. Jack Bailey, President, US Pharmaceuticals at GlaxoSmithKline joined the Board on May 17, 2019.
Phase 1 Completion
DURHAM, N.C. – April 4, 2019 – The Emergo Team is very happy to announce the successful completion of their Phase I trial in March 2019. Robin Hyde/DeRuyscher, CSO stated: “This is a pivotal moment for us and I’m really excited to see our Phase IIa launch in early May 2019.”
Dr. Moise Khayrallah to Receive the 2019 Life Science Leadership Award at the CED Life Science Conference
RTP, NC. – January 28, 2019 — The Council for Entrepreneurial Development (CED) today announced that Moise Khayrallah, Ph.D. will be presented with the Life Science Leadership Award at the 28th Annual CED Life Science Conference, to be held February 26-27 in Raleigh, NC. Dr. Khayrallah will be presented with the award at the Closing Lunch on February 27 which will be open to all registered attendees of the conference.
RALEIGH, N.C. – May 23, 2018 – Emergo Therapeutics has raised $12 million in a Series A funding from a group of investors led by REX Health Ventures (RHV). Other major investors include Wolfpack Investor Network (WIN), Carolina Angel Network (CAN) and the Venture Capital Multiplier Fund at Hatteras Venture Partners.
Will Durham’s Emergo Therapeutics be fourth big startup hit for Moise Khayrallah?
DURHAM, N.C. – June 12, 2018 – Moise Khayrallah, Ph.D., is a serial entrepreneur with a Midas touch. Three biopharmaceutical start-ups he co-founded in recent years were quickly sold to larger companies for more than $400 million after he and his teams built their value from scratch. His latest startup, Durham-based Emergo Therapeutics, could be on a similar path after raising $12 million in venture capital this spring, mostly from North Carolina investors.
Pharma startup Emergo lands $12M from Rex Health Ventures, Triangle backers
DURHAM, N.C. – May 23, 2018 – An all-star list of Triangle investors is backing Durham pharmaceutical startup Emergo Therapeutics with $12 million in venture capital.
Award of NCBiotech Grant
Emergo was awarded a $75,000 Company Inception Loan from the North Carolina Biotechnology Center to further their program